Journal article

Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity

Shorn Goel, Jia Liu, Hao Guo, William Barry, Richard Bell, Bronwyn Murray, Jodi Lynch, Patricia Bastick, Lorraine Chantrill, Belinda E Kiely, Ehtesham Abdi, Josie Rutovitz, Ray Asghari, Anne Sullivan, Michelle Harrison, Maija Kohonen-Corish, Jane Beith

JACC-HEART FAILURE | ELSEVIER SCI LTD | Published : 2019

Abstract

OBJECTIVES: The aim of CATS (Cardiotoxicity of Adjuvant Trastuzumab Study) was to prospectively assess clinical, biochemical, and genomic predictors of trastuzumab-related cardiotoxicity (TRC). BACKGROUND: Cardiac dysfunction is a common adverse effect of trastuzumab. Studies to identify predictive biomarkers for TRC have enrolled heterogeneous populations and yielded mixed results. METHODS: A total of 222 patients with early-stage human epidermal growth factor receptor 2-positive breast cancer scheduled to receive adjuvant anthracyclines followed by 12 months of trastuzumab were prospectively recruited from 17 centers. Left ventricular ejection fraction (LVEF), troponin T, and N-terminal pr..

View full abstract